Experience with selegiline and levodopa in advanced Parkinson's disease
Identifieur interne : 000283 ( Main/Corpus ); précédent : 000282; suivant : 000284Experience with selegiline and levodopa in advanced Parkinson's disease
Auteurs : A. Lieberman ; E. FazziniSource :
- Acta Neurologica Scandinavica [ 0001-6314 ] ; 1991-10.
English descriptors
- KwdEn :
Abstract
We compared the results of treatment with selegiline (deprenyl, Eldepryl) in 17 patients with advanced Stage 4 Parkinson Disease (PD) who were on levodopa (as Sinemet) with 65 Stage 2 or 3 patients with early PD who were also on levodopa. The first group consisted of 17 patients with advanced Stage 4 PD without response fluctuations (“wearing off” or “on off” phenomena). Their mean age was 72.1 ± 7.5 years, their mean duration of PD was 7.4 ± 3.2 years. The second group consisted of 65 patients with Stage 2 or 3 PD who had recently been started on levodopa. Their mean age was 63 ± 12.1 years, their mean duration of PD was 7.4 ± 3.2 years. The mean dose of selegiline was 10.0 ± 1.8 mg per day (range 5–20 mg). The mean duration of treatment was 1.5 ± 0.8 years. During the four years of observation 55.3 ± 8.0% of the Stage 2 or 3 patients improved while only 14.3 ± 13.5% of the Stage 4 patients improved. This difference was significant (p<0.05). During this time 22.0 ± 6.7% of the Stage 2 or 3 patients worsened and 60.7 ± of the Stage 4 patients worsened. This degree of worsening was significant (p<0.05). Adverse effects were minor and reversible. Our observations suggest that selegiline is more effective (higher percent of patients improving, lower percent of patients worsening) when it is added earlier with patients on levodopa than when it is added later.
Url:
DOI: 10.1111/j.1600-0404.1991.tb05022.x
Links to Exploration step
ISTEX:6FCE6AA3CF3BCDB32A770203C4C85803B8469370Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Experience with selegiline and levodopa in advanced Parkinson's disease</title><author><name sortKey="Lieberman, A" sort="Lieberman, A" uniqKey="Lieberman A" first="A." last="Lieberman">A. Lieberman</name><affiliation><mods:affiliation>Movement Disorders, Barrow Neurological Institute Phoenix, Arizona, USA</mods:affiliation></affiliation></author><author><name sortKey="Fazzini, E" sort="Fazzini, E" uniqKey="Fazzini E" first="E." last="Fazzini">E. Fazzini</name><affiliation><mods:affiliation>Clinical Neurology New York University Medical Center New York, New York, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:6FCE6AA3CF3BCDB32A770203C4C85803B8469370</idno><date when="1991" year="1991">1991</date><idno type="doi">10.1111/j.1600-0404.1991.tb05022.x</idno><idno type="url">https://api.istex.fr/document/6FCE6AA3CF3BCDB32A770203C4C85803B8469370/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000283</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Experience with selegiline and levodopa in advanced Parkinson's disease</title><author><name sortKey="Lieberman, A" sort="Lieberman, A" uniqKey="Lieberman A" first="A." last="Lieberman">A. Lieberman</name><affiliation><mods:affiliation>Movement Disorders, Barrow Neurological Institute Phoenix, Arizona, USA</mods:affiliation></affiliation></author><author><name sortKey="Fazzini, E" sort="Fazzini, E" uniqKey="Fazzini E" first="E." last="Fazzini">E. Fazzini</name><affiliation><mods:affiliation>Clinical Neurology New York University Medical Center New York, New York, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Acta Neurologica Scandinavica</title><idno type="ISSN">0001-6314</idno><idno type="eISSN">1600-0404</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1991-10">1991-10</date><biblScope unit="volume">84</biblScope><biblScope unit="issue">S136</biblScope><biblScope unit="page" from="66">66</biblScope><biblScope unit="page" to="69">69</biblScope></imprint><idno type="ISSN">0001-6314</idno></series><idno type="istex">6FCE6AA3CF3BCDB32A770203C4C85803B8469370</idno><idno type="DOI">10.1111/j.1600-0404.1991.tb05022.x</idno><idno type="ArticleID">ANE66</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0001-6314</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>disability</term><term>early treatment</term><term>levodopa</term><term>selegiline</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We compared the results of treatment with selegiline (deprenyl, Eldepryl) in 17 patients with advanced Stage 4 Parkinson Disease (PD) who were on levodopa (as Sinemet) with 65 Stage 2 or 3 patients with early PD who were also on levodopa. The first group consisted of 17 patients with advanced Stage 4 PD without response fluctuations (“wearing off” or “on off” phenomena). Their mean age was 72.1 ± 7.5 years, their mean duration of PD was 7.4 ± 3.2 years. The second group consisted of 65 patients with Stage 2 or 3 PD who had recently been started on levodopa. Their mean age was 63 ± 12.1 years, their mean duration of PD was 7.4 ± 3.2 years. The mean dose of selegiline was 10.0 ± 1.8 mg per day (range 5–20 mg). The mean duration of treatment was 1.5 ± 0.8 years. During the four years of observation 55.3 ± 8.0% of the Stage 2 or 3 patients improved while only 14.3 ± 13.5% of the Stage 4 patients improved. This difference was significant (p<0.05). During this time 22.0 ± 6.7% of the Stage 2 or 3 patients worsened and 60.7 ± of the Stage 4 patients worsened. This degree of worsening was significant (p<0.05). Adverse effects were minor and reversible. Our observations suggest that selegiline is more effective (higher percent of patients improving, lower percent of patients worsening) when it is added earlier with patients on levodopa than when it is added later.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>A. Lieberman</name><affiliations><json:string>Movement Disorders, Barrow Neurological Institute Phoenix, Arizona, USA</json:string></affiliations></json:item><json:item><name>E. Fazzini</name><affiliations><json:string>Clinical Neurology New York University Medical Center New York, New York, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>selegiline</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>levodopa</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>disability</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>early treatment</value></json:item></subject><articleId><json:string>ANE66</json:string></articleId><language><json:string>eng</json:string></language><abstract>We compared the results of treatment with selegiline (deprenyl, Eldepryl) in 17 patients with advanced Stage 4 Parkinson Disease (PD) who were on levodopa (as Sinemet) with 65 Stage 2 or 3 patients with early PD who were also on levodopa. The first group consisted of 17 patients with advanced Stage 4 PD without response fluctuations (“wearing off” or “on off” phenomena). Their mean age was 72.1 ± 7.5 years, their mean duration of PD was 7.4 ± 3.2 years. The second group consisted of 65 patients with Stage 2 or 3 PD who had recently been started on levodopa. Their mean age was 63 ± 12.1 years, their mean duration of PD was 7.4 ± 3.2 years. The mean dose of selegiline was 10.0 ± 1.8 mg per day (range 5–20 mg). The mean duration of treatment was 1.5 ± 0.8 years. During the four years of observation 55.3 ± 8.0% of the Stage 2 or 3 patients improved while only 14.3 ± 13.5% of the Stage 4 patients improved. This difference was significant (p>0.05). During this time 22.0 ± 6.7% of the Stage 2 or 3 patients worsened and 60.7 ± of the Stage 4 patients worsened. This degree of worsening was significant (p>0.05). Adverse effects were minor and reversible. Our observations suggest that selegiline is more effective (higher percent of patients improving, lower percent of patients worsening) when it is added earlier with patients on levodopa than when it is added later.</abstract><qualityIndicators><score>6.517</score><pdfVersion>1.5</pdfVersion><pdfPageSize>591.36 x 795.84 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>5</keywordCount><abstractCharCount>1377</abstractCharCount><pdfWordCount>2577</pdfWordCount><pdfCharCount>16000</pdfCharCount><pdfPageCount>4</pdfPageCount><abstractWordCount>245</abstractWordCount></qualityIndicators><title>Experience with selegiline and levodopa in advanced Parkinson's disease</title><genre><json:string>article</json:string></genre><host><volume>84</volume><publisherId><json:string>ANE</json:string></publisherId><pages><total>4</total><last>69</last><first>66</first></pages><issn><json:string>0001-6314</json:string></issn><issue>S136</issue><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1600-0404</json:string></eissn><title>Acta Neurologica Scandinavica</title><doi><json:string>10.1111/(ISSN)1600-0404</json:string></doi></host><publicationDate>1991</publicationDate><copyrightDate>1991</copyrightDate><doi><json:string>10.1111/j.1600-0404.1991.tb05022.x</json:string></doi><id>6FCE6AA3CF3BCDB32A770203C4C85803B8469370</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/6FCE6AA3CF3BCDB32A770203C4C85803B8469370/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/6FCE6AA3CF3BCDB32A770203C4C85803B8469370/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/6FCE6AA3CF3BCDB32A770203C4C85803B8469370/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Experience with selegiline and levodopa in advanced Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><availability><p>WILEY</p></availability><date>1991</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Experience with selegiline and levodopa in advanced Parkinson's disease</title><author><persName><forename type="first">A.</forename><surname>Lieberman</surname></persName><note type="correspondence"><p>Correspondence: A. Lieberman, Movement Disorders, Barrow Neurological Institute, Phoenix, Arizona 85013, USA</p></note><affiliation>Movement Disorders, Barrow Neurological Institute Phoenix, Arizona, USA</affiliation></author><author><persName><forename type="first">E.</forename><surname>Fazzini</surname></persName><affiliation>Clinical Neurology New York University Medical Center New York, New York, USA</affiliation></author></analytic><monogr><title level="j">Acta Neurologica Scandinavica</title><idno type="pISSN">0001-6314</idno><idno type="eISSN">1600-0404</idno><idno type="DOI">10.1111/(ISSN)1600-0404</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1991-10"></date><biblScope unit="volume">84</biblScope><biblScope unit="issue">S136</biblScope><biblScope unit="page" from="66">66</biblScope><biblScope unit="page" to="69">69</biblScope></imprint></monogr><idno type="istex">6FCE6AA3CF3BCDB32A770203C4C85803B8469370</idno><idno type="DOI">10.1111/j.1600-0404.1991.tb05022.x</idno><idno type="ArticleID">ANE66</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1991</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>We compared the results of treatment with selegiline (deprenyl, Eldepryl) in 17 patients with advanced Stage 4 Parkinson Disease (PD) who were on levodopa (as Sinemet) with 65 Stage 2 or 3 patients with early PD who were also on levodopa. The first group consisted of 17 patients with advanced Stage 4 PD without response fluctuations (“wearing off” or “on off” phenomena). Their mean age was 72.1 ± 7.5 years, their mean duration of PD was 7.4 ± 3.2 years. The second group consisted of 65 patients with Stage 2 or 3 PD who had recently been started on levodopa. Their mean age was 63 ± 12.1 years, their mean duration of PD was 7.4 ± 3.2 years. The mean dose of selegiline was 10.0 ± 1.8 mg per day (range 5–20 mg). The mean duration of treatment was 1.5 ± 0.8 years. During the four years of observation 55.3 ± 8.0% of the Stage 2 or 3 patients improved while only 14.3 ± 13.5% of the Stage 4 patients improved. This difference was significant (p<0.05). During this time 22.0 ± 6.7% of the Stage 2 or 3 patients worsened and 60.7 ± of the Stage 4 patients worsened. This degree of worsening was significant (p<0.05). Adverse effects were minor and reversible. Our observations suggest that selegiline is more effective (higher percent of patients improving, lower percent of patients worsening) when it is added earlier with patients on levodopa than when it is added later.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>selegiline</term></item><item><term>levodopa</term></item><item><term>disability</term></item><item><term>Parkinson's disease</term></item><item><term>early treatment</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1991-10">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/6FCE6AA3CF3BCDB32A770203C4C85803B8469370/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1600-0404</doi><issn type="print">0001-6314</issn><issn type="electronic">1600-0404</issn><idGroup><id type="product" value="ANE"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="ACTA NEUROLOGICA SCANDINAVICA">Acta Neurologica Scandinavica</title></titleGroup></publicationMeta><publicationMeta level="part" position="10000"><doi origin="wiley">10.1111/ane.1991.84.issue-S136</doi><numberingGroup><numbering type="journalVolume" number="84">84</numbering><numbering type="journalIssue">S136</numbering></numberingGroup><coverDate startDate="1991-10">October 1991</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="0006600" status="forIssue"><doi origin="wiley">10.1111/j.1600-0404.1991.tb05022.x</doi><idGroup><id type="unit" value="ANE66"></id></idGroup><countGroup><count type="pageTotal" number="4"></count></countGroup><titleGroup><title type="tocHeading1">Original article</title></titleGroup><copyright>1991 Blackwell Munksgaard</copyright><eventGroup><event type="firstOnline" date="2009-01-29"></event><event type="publishedOnlineFinalForm" date="2009-01-29"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.6 mode:FullText source:HeaderRef result:HeaderRef" date="2010-04-20"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:4.0.1" date="2014-03-15"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-14"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="66">66</numbering><numbering type="pageLast" number="69">69</numbering></numberingGroup><correspondenceTo>A. Lieberman, Movement Disorders, Barrow Neurological Institute, Phoenix, Arizona 85013, USA</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:ANE.ANE66.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="referenceTotal" number="24"></count><count type="linksCrossRef" number="3"></count></countGroup><titleGroup><title type="main">Experience with selegiline and levodopa in advanced Parkinson's disease</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1" corresponding="yes"><personName><givenNames>A.</givenNames><familyName>Lieberman</familyName></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a2"><personName><givenNames>E.</givenNames><familyName>Fazzini</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1" countryCode="US"><unparsedAffiliation>Movement Disorders, Barrow Neurological Institute Phoenix, Arizona, USA</unparsedAffiliation></affiliation><affiliation xml:id="a2" countryCode="US"><unparsedAffiliation>Clinical Neurology New York University Medical Center New York, New York, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">selegiline</keyword><keyword xml:id="k2">levodopa</keyword><keyword xml:id="k3">disability</keyword><keyword xml:id="k4">Parkinson's disease</keyword><keyword xml:id="k5">early treatment</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><p>We compared the results of treatment with selegiline (deprenyl, Eldepryl) in 17 patients with advanced Stage 4 Parkinson Disease (PD) who were on levodopa (as Sinemet) with 65 Stage 2 or 3 patients with early PD who were also on levodopa. The first group consisted of 17 patients with advanced Stage 4 PD without response fluctuations (“wearing off” or “on off” phenomena). Their mean age was 72.1 ± 7.5 years, their mean duration of PD was 7.4 ± 3.2 years. The second group consisted of 65 patients with Stage 2 or 3 PD who had recently been started on levodopa. Their mean age was 63 ± 12.1 years, their mean duration of PD was 7.4 ± 3.2 years. The mean dose of selegiline was 10.0 ± 1.8 mg per day (range 5–20 mg). The mean duration of treatment was 1.5 ± 0.8 years.</p><p>During the four years of observation 55.3 ± 8.0% of the Stage 2 or 3 patients improved while only 14.3 ± 13.5% of the Stage 4 patients improved. This difference was significant (p<0.05). During this time 22.0 ± 6.7% of the Stage 2 or 3 patients worsened and 60.7 ± of the Stage 4 patients worsened. This degree of worsening was significant (p<0.05). Adverse effects were minor and reversible.</p><p>Our observations suggest that selegiline is more effective (higher percent of patients improving, lower percent of patients worsening) when it is added earlier with patients on levodopa than when it is added later.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Experience with selegiline and levodopa in advanced Parkinson's disease</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Experience with selegiline and levodopa in advanced Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Lieberman</namePart><affiliation>Movement Disorders, Barrow Neurological Institute Phoenix, Arizona, USA</affiliation><description>Correspondence: A. Lieberman, Movement Disorders, Barrow Neurological Institute, Phoenix, Arizona 85013, USA</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E.</namePart><namePart type="family">Fazzini</namePart><affiliation>Clinical Neurology New York University Medical Center New York, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">1991-10</dateIssued><copyrightDate encoding="w3cdtf">1991</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="references">24</extent></physicalDescription><abstract lang="en">We compared the results of treatment with selegiline (deprenyl, Eldepryl) in 17 patients with advanced Stage 4 Parkinson Disease (PD) who were on levodopa (as Sinemet) with 65 Stage 2 or 3 patients with early PD who were also on levodopa. The first group consisted of 17 patients with advanced Stage 4 PD without response fluctuations (“wearing off” or “on off” phenomena). Their mean age was 72.1 ± 7.5 years, their mean duration of PD was 7.4 ± 3.2 years. The second group consisted of 65 patients with Stage 2 or 3 PD who had recently been started on levodopa. Their mean age was 63 ± 12.1 years, their mean duration of PD was 7.4 ± 3.2 years. The mean dose of selegiline was 10.0 ± 1.8 mg per day (range 5–20 mg). The mean duration of treatment was 1.5 ± 0.8 years. During the four years of observation 55.3 ± 8.0% of the Stage 2 or 3 patients improved while only 14.3 ± 13.5% of the Stage 4 patients improved. This difference was significant (p<0.05). During this time 22.0 ± 6.7% of the Stage 2 or 3 patients worsened and 60.7 ± of the Stage 4 patients worsened. This degree of worsening was significant (p<0.05). Adverse effects were minor and reversible. Our observations suggest that selegiline is more effective (higher percent of patients improving, lower percent of patients worsening) when it is added earlier with patients on levodopa than when it is added later.</abstract><subject lang="en"><genre>Keywords</genre><topic>selegiline</topic><topic>levodopa</topic><topic>disability</topic><topic>Parkinson's disease</topic><topic>early treatment</topic></subject><relatedItem type="host"><titleInfo><title>Acta Neurologica Scandinavica</title></titleInfo><genre type="Journal">journal</genre><identifier type="ISSN">0001-6314</identifier><identifier type="eISSN">1600-0404</identifier><identifier type="DOI">10.1111/(ISSN)1600-0404</identifier><identifier type="PublisherID">ANE</identifier><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>84</number></detail><detail type="issue"><caption>no.</caption><number>S136</number></detail><extent unit="pages"><start>66</start><end>69</end><total>4</total></extent></part></relatedItem><identifier type="istex">6FCE6AA3CF3BCDB32A770203C4C85803B8469370</identifier><identifier type="DOI">10.1111/j.1600-0404.1991.tb05022.x</identifier><identifier type="ArticleID">ANE66</identifier><accessCondition type="use and reproduction" contentType="copyright">1991 Blackwell Munksgaard</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Blackwell Publishing Ltd</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000283 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000283 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:6FCE6AA3CF3BCDB32A770203C4C85803B8469370
|texte= Experience with selegiline and levodopa in advanced Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |